[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611049":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":43,"collaborators":10,"id":47,"slug":10,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":10,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":10,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Saglik Bilimleri Universitesi","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"patients treated with Yesafili",null,"aflibercept biosimilar used",[13],"Drug: Aflibercept biosimilar (MY-1701P)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Aflibercept biosimilar (MY-1701P)","Patients receiving the aflibercept biosimilar MY-1701P (marketed as Yesafili®) as part of routine clinical care.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Sinan Kalpakoğlu, M.D.","CONTACT","+905380518244","sinankalpakoglu17@gmail.com",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":10,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Prof. Dr. Cemil Taşcıoğlu City Hospital","RECRUITING","Istanbul","şişli","34384","Turkey (Türkiye)",{"type":35,"coordinates":36},"Point",[37,38],28.94966,41.01384,{"lat":38,"lon":37},[41],{"name":42,"role":23,"phone":24,"phoneExt":10,"email":25},"Sinan Kalpakoğlu, m.d.",{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Sinan KALPAKOĞLU, MD","Ophthalmology Consultant, Principal Investigator","100611049",false,"NCT07235527","Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration","Real-World Outcomes of Aflibercept Biosimilar MY-1701P Treatment in Exudative Age-Related Macular Degeneration","Inclusion Criteria:\n\n* Patients aged between 45 and 90 years with active neovascular age-related macular degeneration (nAMD)\n* who show signs of disease activity on routine ophthalmologic examination and optical coherence tomography (OCT)\n* for whom intravitreal injection has already been clinically indicated\n\nExclusion Criteria:\n\n* Patients younger than 45 years or older than 90 years\n* History of stroke, cerebrovascular event, myocardial infarction, or coronary stent placement within the last six months\n* Presence of uveitis\n* Media opacity preventing adequate retinal imaging (e.g., corneal opacity, mature cataract)\n* Coexistence of other retinal vascular diseases (e.g., branch retinal vein occlusion, diabetic macular edema)\n* Presence of hereditary retinal dystrophies\n* Presence of optic atrophy","ALL","45 Years","90 Years",{"count":57,"type":58},54,"ESTIMATED","OBSERVATIONAL","In this study, patients receiving Eylea treatment will be treated with Yesafili, a biosimilar molecule, and routine examination results will be noted.",[62,63,64],"Age Related Macular Degeneration","Exudative Age-Related Macular Degeneration","Anti Vascular Endothelial Growth Factor",[66,67,68,69,70,71],"age related macular degeneration","anti vascular endothelial growth factor","anti-VEGF","aflibercept","macular neovascularization","aflibercept biosimilar","2025-12-05",{"date":74,"type":75},"2025-12-08","ACTUAL",{"date":77,"type":75},"2025-11-20",{"date":79,"type":58},"2026-08-20",{"name":5,"class":6},1]